(Q35820307)

10 August 2017

1 reference

title

The cost of multiple sclerosis and the cost effectiveness of disease-modifying agents in its treatment (English)

1 reference

10 August 2017

0 references

Ceri J Phillips

1

0 references

publication date

1 January 2004

1 reference

10 August 2017

1 reference

10 August 2017

volume

18

1 reference

10 August 2017

issue

9

1 reference

10 August 2017

page(s)

561-574

1 reference

https://scigraph.springernature.com/pub.10.2165/00023210-200418090-00002

10 August 2017

exact match

0 references

cites work

How many people in the world have multiple sclerosis?

1 reference

12 December 2020

Treatment of secondary progressive multiple sclerosis: current recommendations and future prospects

1 reference

12 December 2020

[Early multiple sclerosis therapy in the effects of public health economics]

1 reference

12 December 2020

Outcomes assessment of drug treatment in multiple sclerosis clinical trials

1 reference

12 December 2020

Evidence for genetic basis of multiple sclerosis. The Canadian Collaborative Study Group.

1 reference

12 December 2020

Use and misuse of statistics for epidemiological studies of multiple sclerosis

1 reference

12 December 2020

Offspring recurrence rates and clinical characteristics of conjugal multiple sclerosis

1 reference

12 December 2020

What is new in the treatment of multiple sclerosis?

1 reference

12 December 2020

Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide

1 reference

12 December 2020

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

1 reference

12 December 2020

Quality of life among persons with multiple sclerosis and their caregivers.

1 reference

12 December 2020

Is there a kink in consumers' threshold value for cost-effectiveness in health care?

1 reference

12 December 2020

Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group

1 reference

12 December 2020

The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course

1 reference

12 December 2020

Multiple sclerosis among United Kingdom-born children of immigrants from the Indian subcontinent, Africa and the West Indies

1 reference

12 December 2020

A cost-utility analysis of interferon beta for multiple sclerosis

1 reference

12 December 2020

The economics of multiple sclerosis. Distribution of costs and relationship to disease severity

1 reference

12 December 2020

Cost-effectiveness of measuring fractional flow reserve to guide coronary interventions

1 reference

12 December 2020

The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability

1 reference

12 December 2020

Quality of life in multiple sclerosis in France, Germany, and the United Kingdom. Cost of Multiple Sclerosis Study Group

1 reference

12 December 2020

Cost-effectiveness analysis of interferon beta in multiple sclerosis: a Markov process analysis

1 reference

12 December 2020

The management of multiple sclerosis: current and future therapies

1 reference

12 December 2020

The current therapy of multiple sclerosis

1 reference

12 December 2020

Health economic evaluations using decision analytic modeling. Principles and practices--utilization of a checklist to their development and appraisal

1 reference

12 December 2020

Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis

1 reference

12 December 2020

Long-term treatment of multiple sclerosis with interferon-beta may be cost effective

1 reference

12 December 2020

A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models.

1 reference

12 December 2020

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group

1 reference

12 December 2020

Cost-effectiveness of interferon beta-1b in slowing multiple sclerosis disability progression. First estimates.

1 reference

12 December 2020

The British Isles survey of multiple sclerosis in twins

1 reference

12 December 2020

Cost-utility analysis of interferon beta-1b in secondary progressive multiple sclerosis

1 reference

12 December 2020

The value of economic modeling studies in the evaluation of treatment strategies for multiple sclerosis

1 reference

12 December 2020

Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis

1 reference

12 December 2020

1 reference

12 December 2020

[Multiple sclerosis: cost of the illness]

1 reference

12 December 2020

Quality of life in multiple sclerosis. Comparison with inflammatory bowel disease and rheumatoid arthritis

1 reference

12 December 2020

Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosis

1 reference

12 December 2020

The economic cost of multiple sclerosis in Sweden in 1994.

1 reference

12 December 2020

The use of standardized incidence and prevalence rates in epidemiological studies on multiple sclerosis. A meta-analysis study

1 reference

12 December 2020

Disease-modifying drugs for multiple sclerosis: a rapid and systematic review

1 reference

12 December 2020

Epidemiology of multiple sclerosis: a critical overview.

1 reference

12 December 2020

Immunomodulatory drugs for multiple sclerosis: a systematic review of clinical and cost effectiveness

1 reference

12 December 2020

Burden of illness of multiple sclerosis: Part I: Cost of illness. The Canadian Burden of Illness Study Group

1 reference

12 December 2020

Neuroimaging evaluation in multiple sclerosis

1 reference

12 December 2020

Treating the family with multiple sclerosis

1 reference

12 December 2020

A comprehensive assessment of the cost of multiple sclerosis in the United States.

1 reference

12 December 2020

Cost-utility of interferon beta1b in the treatment of patients with active relapsing-remitting or secondary progressive multiple sclerosis.

1 reference

12 December 2020

Age-adjusted recurrence risks for relatives of patients with multiple sclerosis.

1 reference

12 December 2020

Burden of illness of multiple sclerosis: Part II: Quality of life. The Canadian Burden of Illness Study Group

1 reference

12 December 2020

Interferon-beta in multiple sclerosis. Can we control its costs?

1 reference

12 December 2020

Cost-utility analysis of interferon beta-1B in secondary progressive multiple sclerosis using natural history disease data.

1 reference

12 December 2020

Economic consequences of multiple sclerosis for Canadians

1 reference

12 December 2020

Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis.

1 reference

12 December 2020

Caregivers of people with multiple sclerosis: a survey in New Zealand.

1 reference

12 December 2020

Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS

1 reference

12 December 2020

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

1 reference

12 December 2020

Choosing drug therapy for multiple sclerosis. An update.

1 reference

12 December 2020

'Quick and clean': authoritative health technology assessment for local health care contracting

1 reference

12 December 2020

Impairment, disability, and handicap in multiple sclerosis. A cross-sectional study in an incident cohort in Møre and Romsdal County, Norway

1 reference

12 December 2020

The costs of multiple sclerosis: a cross-sectional, multicenter cost-of-illness study in Italy

1 reference

12 December 2020

Interferon beta therapy for multiple sclerosis

1 reference

12 December 2020

Relapsing-remitting multiple sclerosis: what is the potential for combination therapy?

1 reference

12 December 2020

Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group

1 reference

12 December 2020

1 reference

12 December 2020

Quality of life and cost of multiple sclerosis

1 reference

12 December 2020

Costs, quality of life and disease severity in multiple sclerosis: a cross-sectional study in Sweden.

1 reference

12 December 2020

Cognitive dysfunction in multiple sclerosis.: II. Impact on employment and social functioning

1 reference

12 December 2020

Systematic review of immunomodulatory drugs for the treatment of people with multiple sclerosis: Is there good quality evidence on effectiveness and cost?

1 reference

12 December 2020

Human recombinant interferon beta in the treatment of relapsing-remitting multiple sclerosis: preliminary observations

1 reference

12 December 2020

Economic Evaluation of Multiple Sclerosis in the UK, Germany and France

1 reference

12 December 2020

Interferons in relapsing remitting multiple sclerosis: a systematic review

1 reference

12 December 2020

Treatment of multiple sclerosis with interferon beta: an appraisal of cost-effectiveness and quality of life

1 reference

12 December 2020

Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines

1 reference

12 December 2020

10.2165/00023210-200418090-00002

Identifiers

DOI

1 reference

Dimensions Publication ID

10 August 2017

1033969061

0 references

1 reference